December 25th 2025, 4:00pm
BOOG 13-08 shows skipping sentinel lymph node biopsy in patients 50+ with early-stage, hormone receptor–positive, HER2-negative breast cancer is safe.
December 23rd 2025, 8:00pm
At the 2025 SABCS, researchers presented findings with the potential to meaningfully affect breast cancer treatment and patient care.
December 22nd 2025, 8:00pm
DESTINY-Breast05 analyses show post neoadjuvant Enhertu improves invasive disease free survival compared with Kadcyla in patients with residual early stage breast cancer.
December 12th 2025, 10:06pm
Most premenopausal women with early breast cancer accepted GnRHa during chemotherapy to preserve ovarian function; cryopreservation uptake was lower.
December 12th 2025, 10:01pm
Inluriyo and Verzenio helped patients with ER+/HER2– advanced breast cancer stay on treatment longer without their disease worsening vs standard therapy.
December 12th 2025, 6:11pm
Hormone therapy after breast cancer did not increase risk in BRCA1/2 carriers; estrogen alone was linked to lower risk.
December 12th 2025, 5:10pm
For AYA breast cancer survivors, mobile health intervention was associated with improvements to general and cancer-specific quality of life.
December 12th 2025, 4:07pm
Real and sham acupuncture improved perceived cognitive function versus usual care, with real acupuncture showing greater benefits for objective cognitive outcomes.
December 11th 2025, 6:46pm
The 60-month local regional recurrence-free rate was 93.2% in the MRI arm versus 95.7% in the no MRI arm, researchers reported.
December 11th 2025, 5:51pm
Enhertu and Perjeta led to better quality-of-life and less side effects than standard-of-care among patients with HER2+ advanced or metastatic breast.
Orserdu Combo Shows Potential for ER+/HER2– Breast Cancer
Advice for Patients Newly Diagnosed With Lung Cancer
Omitting Sentinel Lymph Node Biopsy Safe in Older Breast Cancer
How Nutrition Impacts Breast Cancer Risk and Recovery